日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV

一项随机 I 期研究，旨在评估高浓度长效卡博特韦制剂在非 HIV 感染成人中的药代动力学、安全性和耐受性。

期刊:Clinical Pharmacology in Drug Development
影响因子:
doi:10.1002/cpdd.1538
Han, Kelong; Benn, Paul; Sievers, Jörg; Dorey, David; Warwick-Sanders, Michael; Hareedy, Randa; Harkness, Louise; Leemereise, Claudia; Offenbecker, Kjersten; Donatti, Christina; Brimhall, Darin B; Schwabe, Christian; Boyle, Craig; Hassman, Michael A; Knowles, Steve; D'Amico, Ronald; Spreen, William R
HIV
炎症/感染
微生物学
发表日期：2025
文献求助 收藏

VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results

VH3810109 (N6LS) 广谱中和抗体在非 HIV 感染成人中的安全性、药代动力学和抗药抗体发生率：1 期 SPAN 研究结果

期刊:Antimicrobial Agents and Chemotherapy
影响因子:
doi:10.1128/aac.00258-25
Leone, Peter A; Losos, Jan; Wannamaker, Paul; D'Agostino, Riccardo; Warwick-Sanders, Michael; Ghita, Gabriela L; Wilches, Viviana; Donatti, Christina; Brown, Kathryn; Gandhi, Yash
HIV
炎症/感染
微生物学
发表日期：2025
文献求助 收藏

VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results

VH3810109 抗逆转录病毒疗法初治 HIV-1 感染成人患者的疗效、安全性、药代动力学及抗药抗体发生率：BANNER 研究结果

期刊:Journal of Infectious Diseases
影响因子:
doi:10.1093/infdis/jiaf450
Leone, Peter A; Ferro, Alejandro; Rolle, Charlotte-Paige; Lupo, Sergio; McGowan, Joseph; Klein, Marina; Cahn, Pedro; Benson, Paul; Griesel, Rulan; Warwick-Sanders, Michael; Sanchez, Marisa; D'Agostino, Riccardo; Bettacchi, Christopher; Schneider, Stefan; Wannamaker, Paul; Dorey, David; Wilches, Viviana; Gartland, Margaret; Brown, Kathryn; Gandhi, Yash; Donatti, Christina; Losos, Jan
HIV
炎症/感染
微生物学
发表日期：2025
文献求助 收藏

Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study

在 3 期 BRIGHTE 研究中，对接受 fostemsavir 治疗长达 5 年的、接受过大量治疗的成年患者进行长期安全性评估以及对免疫恢复的影响

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1394644
Llibre, Josep M; Aberg, Judith A; Walmsley, Sharon; Velez, Juan; Zala, Carlos; Crabtree Ramírez, Brenda; Shepherd, Bronagh; Shah, Rimi; Clark, Andrew; Tenorio, Allan R; Pierce, Amy; Du, Fangfang; Li, Bo; Wang, Marcia; Chabria, Shiven; Warwick-Sanders, Michael
免疫/内分泌
发表日期：2024
文献求助 收藏